Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Price
Target price
€75.52

€75.52

0.880%
0.66
0.880%
€124.00

€124.00

 
09:48 / Tradegate WKN: 663200 / Name: MorphoSys / Stock / Biotechnology & Medical Research / Mid Cap /
Latest predictions
-
08.03.21
buy
-
29.12.20
buy
€100.00
19.11.20
buy
-
29.10.20
€130.00
06.08.20
buy
€130.00
15.07.20
buy
Your prediction

MorphoSys AG Stock

MorphoSys AG gained 0.880% compared to yesterday.
We see a rather positive sentiment for MorphoSys AG with 12 Buy predictions and 2 Sell predictions.
As a result the target price of €124.00 shows a very positive potential of 64.195% compared to the current price of €75.52 for MorphoSys AG.
Criterium "Worthwhile Investment for the next years" is seen as the biggest plus for MorphoSys AG stock. Negative votes have not been in the majority for any criteria for this stock

Pros and Cons of MorphoSys AG in the next few years

Pros
2
Could be worthwhile Investment >10% per year
2
Revenue growth >5% per year expected
2
positive Cash Flow expected
Cons
0
-

Performance of MorphoSys AG vs. its peers

Security Change (%) 1w 1m 1y YTD 3y 5y
MorphoSys AG 0.880% 0.187% -12.751% -18.096% -20.209% -9.916% 52.065%
Evotec AG -0.030% 5.806% 15.839% 47.828% 10.650% 126.871% 862.760%
Ionis Pharmaceuticals Inc. 0.260% -13.618% -22.410% -29.055% -26.128% -1.771% -8.588%
Nektar Therapeutics 0.730% -7.974% -17.689% -8.505% 5.662% - -

Comments

Buy MorphoSys AG
Show more

Sell Morphosys AG
Show more

Buy Morphosys AG
Show more

Other discussions about MorphoSys AG Stock

Trading Morphosys AG

Trading Morphosys AG

New thread Forum

News

DGAP-News: MorphoSys' Licensee Announces Approval by the European Commission for Tremfya(R) (guselkumab) for Treatment of Adults with Active Psoriatic Arthritis (PsA) : http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24061/Morphosys-logo.svg.png
DGAP-News: MorphoSys' Licensee Announces Approval by the European Commission for Tremfya(R) (guselkumab) for Treatment of Adults with Active Psoriatic Arthritis (PsA)
DGAP-News: MorphoSys' Licensee Announces Approval by the European Commission for Tremfya(R) (guselkumab) for Treatment of Adults with Active Psoriatic Arthritis (PsA)
DGAP-News: Thomas Biegi Joins MorphoSys as  Head of Corporate Communications: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24061/Morphosys-logo.svg.png
DGAP-News: Thomas Biegi Joins MorphoSys as Head of Corporate Communications
DGAP-News: Thomas Biegi Joins MorphoSys as Head of Corporate Communications
DGAP-News: MorphoSys Reports Nine Months and Third Quarter  2020 Results: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24061/Morphosys-logo.svg.png
DGAP-News: MorphoSys Reports Nine Months and Third Quarter 2020 Results
DGAP-News: MorphoSys Reports Nine Months and Third Quarter 2020 Results